BRPI0912249A2 - método de prevenir o desenvolvimento de artrite reumatoide em indivíduos com artrite não diferenciada. - Google Patents

método de prevenir o desenvolvimento de artrite reumatoide em indivíduos com artrite não diferenciada.

Info

Publication number
BRPI0912249A2
BRPI0912249A2 BRPI0912249A BRPI0912249A BRPI0912249A2 BR PI0912249 A2 BRPI0912249 A2 BR PI0912249A2 BR PI0912249 A BRPI0912249 A BR PI0912249A BR PI0912249 A BRPI0912249 A BR PI0912249A BR PI0912249 A2 BRPI0912249 A2 BR PI0912249A2
Authority
BR
Brazil
Prior art keywords
arthritis
individuals
development
preventing
undifferentiated
Prior art date
Application number
BRPI0912249A
Other languages
English (en)
Inventor
George Vratsanos
Jean-Claude Becker
Michael Corbo
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41264941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0912249(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI0912249A2 publication Critical patent/BRPI0912249A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
BRPI0912249A 2008-05-05 2009-05-05 método de prevenir o desenvolvimento de artrite reumatoide em indivíduos com artrite não diferenciada. BRPI0912249A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5033608P 2008-05-05 2008-05-05
US12/387,359 US7915222B2 (en) 2008-05-05 2009-05-01 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
PCT/US2009/042761 WO2009137424A1 (en) 2008-05-05 2009-05-05 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Publications (1)

Publication Number Publication Date
BRPI0912249A2 true BRPI0912249A2 (pt) 2015-10-20

Family

ID=41264941

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0912249A BRPI0912249A2 (pt) 2008-05-05 2009-05-05 método de prevenir o desenvolvimento de artrite reumatoide em indivíduos com artrite não diferenciada.

Country Status (25)

Country Link
US (3) US7915222B2 (pt)
EP (2) EP2891665A1 (pt)
JP (1) JP2011522795A (pt)
KR (1) KR20110014180A (pt)
CN (1) CN102037010A (pt)
AR (1) AR071672A1 (pt)
AU (1) AU2009244448B2 (pt)
BR (1) BRPI0912249A2 (pt)
CA (1) CA2723698C (pt)
CL (1) CL2009001082A1 (pt)
DK (1) DK2279206T3 (pt)
EA (1) EA201001749A1 (pt)
ES (1) ES2539840T3 (pt)
HK (2) HK1208230A1 (pt)
HR (1) HRP20150552T1 (pt)
HU (1) HUE025256T2 (pt)
IL (1) IL208691A (pt)
MX (1) MX2010011503A (pt)
NZ (1) NZ589020A (pt)
PL (1) PL2279206T3 (pt)
PT (1) PT2279206E (pt)
SI (1) SI2279206T1 (pt)
TW (2) TWI454278B (pt)
WO (1) WO2009137424A1 (pt)
ZA (1) ZA201007914B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
JP6239517B2 (ja) * 2011-10-10 2017-11-29 メディミューン リミテッド 関節リウマチの治療法
US20140006055A1 (en) * 2012-06-27 2014-01-02 Iagnosis, Inc. Integrated Medical Evaluation and Record Keeping System
EP2914292A4 (en) * 2012-10-30 2016-05-04 Univ Emory STIMULATION OF BONE FORMATION BY INHIBITING CD28 COSTIMULATION
WO2014151230A2 (en) * 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Method of treating granulomatosis with polyangiitis
KR20160145789A (ko) * 2014-04-25 2016-12-20 브리스톨-마이어스 스큅 컴퍼니 초기 ra를 갖는 대상체에서의 무약물 완화를 달성하기 위한 ctla4 화합물의 용도
CN107969128A (zh) 2015-04-17 2018-04-27 高山免疫科学股份有限公司 具有可调的亲和力的免疫调节蛋白
EP3694870A1 (en) 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
CN110148465B (zh) * 2019-05-10 2023-07-04 中山大学孙逸仙纪念医院 一种用于分析类风湿性关节炎的系统

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070776B1 (en) 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
AU661854B2 (en) 1991-06-27 1995-08-10 Bristol-Myers Squibb Company CTL4A receptor, fusion proteins containing it and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
BR9405664A (pt) * 1993-01-21 1996-04-30 Univ Georgia Composto imunogenio processos para evitar a toxicose por festuca em um herbivoro para tratar a toxicose por festuca em um herbivoro anticorpo purificado lingagem de célula de hidridoma e anticorpo
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
WO1997034633A1 (en) 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
US20030219863A1 (en) 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
AU7541101A (en) 2000-06-09 2001-12-24 Bristol Myers Squibb Co Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
AU2001273174B2 (en) 2000-07-03 2006-05-18 Bristol-Myers Squibb Company Methods for treating rheumatic diseases using a soluble CTLA4 molecule
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
HUP0303930A3 (en) 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
AU2002305716B2 (en) 2001-05-23 2007-10-25 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
CA2508925C (en) 2002-12-23 2012-08-28 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
CA2511520A1 (en) 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
MXPA06001225A (es) 2003-08-04 2006-04-11 Bristol Myers Squibb Co Metodos de tratamiento de enfermedad cardiovascular usando una molecula soluble de ctla4.
US10092429B2 (en) * 2005-08-22 2018-10-09 Incept, Llc Flared stents and apparatus and methods for delivering them
BRPI0611707A2 (pt) 2005-06-29 2012-04-24 Compumedics Ltd conjunto de sensor com ponte condutiva
AR058567A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Formulaciones de proteinas estables
PL2253644T3 (pl) 2005-12-20 2014-04-30 Bristol Myers Squibb Co Kompozycje i sposoby wytwarzania kompozycji
US7528111B2 (en) 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Also Published As

Publication number Publication date
ZA201007914B (en) 2011-07-27
EA201001749A1 (ru) 2011-06-30
US9012408B2 (en) 2015-04-21
US20130195865A1 (en) 2013-08-01
US8435952B2 (en) 2013-05-07
HK1208230A1 (en) 2016-02-26
US20110142835A1 (en) 2011-06-16
EP2891665A1 (en) 2015-07-08
EP2279206A4 (en) 2011-05-25
KR20110014180A (ko) 2011-02-10
JP2011522795A (ja) 2011-08-04
WO2009137424A1 (en) 2009-11-12
NZ589020A (en) 2012-05-25
TW200948381A (en) 2009-12-01
AR071672A1 (es) 2010-07-07
SI2279206T1 (sl) 2015-08-31
PL2279206T3 (pl) 2015-09-30
DK2279206T3 (en) 2015-07-27
PT2279206E (pt) 2015-07-27
AU2009244448B2 (en) 2014-07-31
HK1148291A1 (en) 2011-09-02
TWI454278B (zh) 2014-10-01
CN102037010A (zh) 2011-04-27
ES2539840T3 (es) 2015-07-06
MX2010011503A (es) 2010-11-09
IL208691A0 (en) 2010-12-30
TW201444575A (zh) 2014-12-01
US7915222B2 (en) 2011-03-29
HUE025256T2 (en) 2016-02-29
CL2009001082A1 (es) 2010-02-12
EP2279206B1 (en) 2015-04-22
IL208691A (en) 2015-01-29
US20090280119A1 (en) 2009-11-12
HRP20150552T1 (hr) 2015-06-19
CA2723698C (en) 2018-03-06
AU2009244448A1 (en) 2009-11-12
CA2723698A1 (en) 2009-11-12
EP2279206A1 (en) 2011-02-02

Similar Documents

Publication Publication Date Title
BRPI0912249A2 (pt) método de prevenir o desenvolvimento de artrite reumatoide em indivíduos com artrite não diferenciada.
BRPI0917120A2 (pt) método, e, meio legível por computador.
BRPI0922312A2 (pt) método, e, meio legível por computador
BRPI0818272A2 (pt) Antígeno associado com artrite reumatóide
BRPI0817475A2 (pt) meio legível por computador.
BRPI0810746A2 (pt) Dispositivos e sistemas de células de combustível e respectivos métodos de produção e de uso.
BRPI0914208A2 (pt) célula de eletrólise, e, método
BRPI0814467A2 (pt) Método, e, biocombustível
NO20073935L (no) Tetningsarrangement, samt tilhorende fremgangsmate
BRPI0813710A2 (pt) Enzimas que produzem acetil-coa em levedura
BRPI1015379A2 (pt) sistemas de cálculo biométrico e métodos
BRPI0913227A2 (pt) método, e objeto
BRPI0814466A2 (pt) Método.
EP2508487A4 (en) WASTEWATER PRETREATMENT METHOD AND EFFLUENT TREATMENT METHOD USING THE PRETREATMENT PROCESS
BRPI0919724A2 (pt) unidade de processamento, e , meio legível por computador
BRPI0913112A2 (pt) fluxímetro, e, método.
BRPI0920736A2 (pt) módulo de placa e método de fabricação do mesmo.
BRPI0811236A2 (pt) Embarcação, e, método de amarração.
IT1397197B1 (it) Veicolo battipista e relativo metodo di controllo.
BRPI0906438A2 (pt) Isolamento de conteúdo por meio de processos em uma aplicação
BRPI0923059A2 (pt) escareador e placas de lâminas.
BRPI0808218A2 (pt) simulador de corrosão e o método correspondente
DK2068922T3 (da) Anti-IL-13Ralfa1-antistoffer samt deres anvendelser
IT1397194B1 (it) Veicolo battipista e relativo metodo di controllo.
NL2002886A1 (nl) Prognostic method.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.